Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 5/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | PPARA | Q07869 | 1/20 | 0.43 |
| ▸ | ATR | Q13535 | 1/20 | 0.42 |
| ▸ | BTK | Q06187 | 7/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6325803 | 0.93 | ADORA2A (0.42) | DGAT1NPC1RAB9APPARAMAPT | |
| Trifluoroacetic Acid SCHEMBL6333105 | 0.92 | DGAT1 (0.51) | DGAT1NPC1RAB9AGAAPPARA | |
| Trifluoroacetic Acid SCHEMBL6325797 | 0.85 | PPARA (0.49) | DGAT1NPC1RAB9APPARAMAPT | |
| SCHEMBL6332860 | 0.83 | MAPT (0.43) | DGAT1NPC1RAB9AMEN1KMT2A | |
| SCHEMBL6326610 | 0.83 | DGAT1 (0.47) | DGAT1NPC1RAB9AGAAATR | |
| SCHEMBL6337266 | 0.83 | DGAT1 (0.51) | DGAT1NPC1RAB9AGAAATR | |
| SCHEMBL6327445 | 0.81 | MAPT (0.44) | DGAT1NPC1RAB9AGAABTK | |
| SCHEMBL6328366 | 0.81 | MAPT (0.41) | DGAT1NPC1RAB9AMAPT | |
| SCHEMBL6326588 | 0.80 | DGAT1 (0.49) | DGAT1NPC1RAB9AGAAPPARA | |
| SCHEMBL5727205 | 0.79 | DGAT1 (0.46) | DGAT1NPC1RAB9AGAAATR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050014805-A1 | Phenyl substituted 5-membered nitrogen containing heterocycles for the treatment of obesity | BAYER PHARMACEUTICALS CORPORATION | 2005-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014805-A1 | Phenyl substituted 5-membered nitrogen containing heterocycles for the treatment of obesity | GPR119, EGLN3, PC | DGAT1 386/4885NPC1 315/4885RAB9A 2132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.